Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Juno Pharmaceuticals Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (254)
Cancellation by sponsor (91)
Prescription medicine registration (28)
Section 14, TGO91 consent (6)
Australian Public Assessment Report (AusPAR) (1)
Prescription medicine decision summary (1)

Date

2026 (13)
2025 (23)
2024 (13)
2023 (11)
2022 (35)
2021 (68)
2020 (45)
2019 (51)
2018 (18)
2017 (14)
2016 (16)
2015 (13)
2014 (7)
2013 (8)
2012 (12)
2011 (5)
2010 (1)
2009 (2)
2007 (1)
2006 (4)
2003 (7)
2000 (1)
1999 (2)
1998 (1)
1996 (3)
1994 (2)
1991 (5)

Search

Sponsor content

381 result(s) found, displaying 211 to 220

CAPECITABINE AN capecitabine 150 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2021

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
LETROZOLE AN letrozole 2.5 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2021

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
LANPRO latanoprost 50 micrograms/mL eye drop solution bottle Cancelled under Section 30(1)(c) of the Act

30 June 2021

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
BICALIDE bicalutamide 50mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2021

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
LENALEX, LENALIDE, LENALIDOMIDE JUNO (Juno Pharmaceuticals Pty Ltd)

22 June 2021

Prescription medicine registration

Active ingredients: lenalidomide.
POMALIDOMIDE JN, POMALIDOMIDE JUNO, POMOLIDE (Juno Pharmaceuticals Pty Ltd)

14 April 2021

Prescription medicine registration

Active ingredients: pomalidomide.
TOROLAK ketorolac trometamol 30 mg/1 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

6 April 2021

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
VANCOMYCIN JUNO (Juno Pharmaceuticals Pty Ltd)

23 February 2021

Prescription medicine registration

Active ingredients: vancomycin hydrochloride.
DOPAMINE JUNO (Juno Pharmaceuticals Pty Ltd)

18 February 2021

Prescription medicine registration

Active ingredients: dopamine hydrochloride.
ASTRAZENECA PETHIDINE pethidine hydrochloride 100mg/2mL injection BP ampoule Cancelled under Section 30(1)(c) of the Act

11 February 2021

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd

Pages

First page
Previous page
…
Page 18
Page 19
Page 20
Page 21
Current page 22
Page 23
Page 24
Page 25
Page 26
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.